GlassScriptPhysician profile
Ballard J Mann
NPI 1942580048
$3,109.03
in general payments reported to CMS, 2019-2025
23 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $900 · 2023: $713 · 2024: $408 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $379.70 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $363.62 | 2021-2025 | |
| Novo Nordisk INC | $354.15 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $340.58 | 2022-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $260.38 | 2021-2024 | Trintellix |
| Abbvie INC. | $191.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $164.97 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $140.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $135.20 | 2021-2022 | |
| Pfizer INC. | $117.68 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $117.50 | 2021-2025 | Belsomra, Gardasil 9, Capvaxive |
| Kowa Pharmaceuticals America, INC. | $109.07 | 2021-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.90 | 2021-2024 | Jardiance |
| Amgen INC. | $76.24 | 2022-2023 | Repatha |
| Xeris Pharmaceuticals, INC. | $65.61 | 2021-2025 | Keveyis |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $56.82 | 2021-2025 | Breztri |
| Sanofi Pasteur INC. | $36.18 | 2025 | |
| Dexcom, INC. | $24.76 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $24.07 | 2025 | |
| Adlon Therapeutics L.P. | $16.97 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.73 | 2022 | |
| Inspire Medical Systems, INC. | $14.38 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $13.36 | 2023 | Daybue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ballard Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.